Compare · ANABV vs NVO
ANABV vs NVO
Side-by-side comparison of AnaptysBio Inc. (ANABV) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANABV and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $168.79B.
- Both names hit the wire about 4 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 0 for ANABV).
- Company
- AnaptysBio Inc.
- Novo Nordisk A/S
- Price
- -
- $39.23+2.88%
- Market cap
- -
- $168.79B
- 1M return
- -
- -5.98%
- 1Y return
- -
- -30.04%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 4
- 4
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ANABV
- Director Renton Hollings exercised 5,000 shares at a strike of $18.03 and sold $249,372 worth of shares (5,000 units at $49.87) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by AnaptysBio Inc.
- SEC Form 10-KT filed by AnaptysBio Inc.
- AnaptysBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Director Orwin John A converted options into 1,300 shares, increasing direct ownership by 8% to 17,995 units (SEC Form 4)
- AnaptysBio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 4 filed by Chief Medical Officer Lizzul Paul F.
- SEC Form 4 filed by President, CEO Faga Daniel
- AnaptysBio Inc. filed SEC Form 8-K: Regulation FD Disclosure
- SEC Form 144 filed by AnaptysBio Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank